Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.60 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.60 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.60 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.60 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264310 | 0.91 | GABRA1 (0.61) | KDM4EGABRA1GABRB2HPGDHSD17B10 | |
| SCHEMBL4261723 | 0.90 | KDM4E (0.57) | KDM4EGABRA1GABRB2HPGDHSD17B10 | |
| SCHEMBL4255619 | 0.89 | GABRA1 (0.56) | KDM4EGABRA1GABRB2HPGDHSD17B10 | |
| SCHEMBL4263928 | 0.88 | KDM4E (0.53) | KDM4EGABRA1GABRB2HPGDHSD17B10 | |
| SCHEMBL4259250 | 0.87 | GABRA1 (0.54) | KDM4EGABRA1GABRB2HPGDHSD17B10 | |
| SCHEMBL4261070 | 0.86 | NR1H4 (0.55) | KDM4EGABRA1GABRB2HPGDHSD17B10 | |
| SCHEMBL4253107 | 0.86 | GABRA1 (0.53) | KDM4EGABRA1GABRB2HPGDHSD17B10 | |
| SCHEMBL4261710 | 0.84 | GABRA1 (0.59) | KDM4EGABRA1GABRB2HPGDHSD17B10 | |
| SCHEMBL4257110 | 0.83 | TP53 (0.54) | KDM4EGABRA1GABRB2HPGDHSD17B10 | |
| SCHEMBL2930904 | 0.82 | GABRA1 (0.70) | KDM4EGABRA1GABRB2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814880-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INT (ES) | 2009-01-28 | — | — | EP | claimed |
| US-20080200473-A1 | Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto | FERRER INTERNACIONAL, S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| EP-1814880-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2007-08-08 | — | — | EP | claimed |
| WO-2006051063-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INTERNACIONAL S. A. (ES) | 2006-05-18 | — | — | WO | claimed |
| EP-1814880-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INT (ES) | 2009-01-28 | — | — | EP | disclosed |
| EP-1814880-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INT (ES) | 2009-01-28 | — | — | EP | disclosed |
| US-20080200473-A1 | Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto | FERRER INTERNACIONAL, S.A. (ES) | 2008-08-21 | — | — | US | disclosed |
| US-20080200473-A1 | Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto | FERRER INTERNACIONAL, S.A. (ES) | 2008-08-21 | — | — | US | disclosed |
| US-20080200473-A1 | Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto | FERRER INTERNACIONAL, S.A. (ES) | 2008-08-21 | — | — | US | disclosed |
| EP-1814880-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006051063-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INTERNACIONAL S. A. (ES) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006051063-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INTERNACIONAL S. A. (ES) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200473-A1 | Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto | GABRA1, GABRA2, GABRA3 | KDM4E 2980/4885GABRA1 1/4885GABRB2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.